Literature DB >> 8038493

Chronic lymphocytic leukaemia: prognostic factors and natural history.

E Montserrat1, C Rozman.   

Abstract

In the past 20 years, important progress has been made in the understanding of the natural history and prognosis of chronic lymphocytic leukaemia (CLL). Based on the notion that the clinical manifestations of CLL are due primarily to the progressive accumulation of lymphocytes over time, several prognostic factors have been identified. The prognostic value of parameters reflecting tumour burden (i.e. lymphadenopathy, splenomegaly, anaemia and/or thrombocytopenia due to bone marrow failure), first identified empirically, has been confirmed in multivariate analyses of large series of patients. Furthermore, clinical staging systems that group the most relevant of these factors have also been developed. Patients in early stage (Binet A; Rai 0) have a long survival which, in some cases, may match that of the general population. In contrast, patients with advanced stage (Binet C; Rai III or IV) have a median survival < 2 years. The major limitation of staging systems is that they do not give information about the likelihood of progression for patients in early stage. Nevertheless, haemoglobin level, blood lymphocyte count, lymphocyte doubling time and bone marrow infiltration pattern are useful to identify subsets of patients in early stage with different progression and survival rates, with the 'smouldering' form of the disease being identified fairly accurately. With all these advances, therapy in CLL can now be indicated on a more rational basis. However, further biological insight is needed to elucidate the mechanism accounting for the different forms of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8038493     DOI: 10.1016/s0950-3536(05)80179-9

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  5 in total

1.  Chronic lymphocytic leukaemia: a-twenty-years experience and problems in Ile-Ife, South-Western Nigeria.

Authors:  L Salawu; R A Bolarinwa; M A Durosinmi
Journal:  Afr Health Sci       Date:  2010-06       Impact factor: 0.927

Review 2.  Achieving optimal outcomes in chronic lymphocytic leukaemia.

Authors:  T J Hamblin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia.

Authors:  J F DeCoteau; P I Knaus; H Yankelev; M D Reis; R Lowsky; H F Lodish; M E Kadin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

4.  Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.

Authors:  Grzegorz S Nowakowski; James D Hoyer; Tait D Shanafelt; Clive S Zent; Timothy G Call; Nancy D Bone; Betsy Laplant; Gordon W Dewald; Renee C Tschumper; Diane F Jelinek; Thomas E Witzig; Neil E Kay
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

5.  Chronic Lymphocytic Leukemia: Prognostic Factors at Presentation in a Resource-Limited Center.

Authors:  Kaladada Ibitrokoemi Korubo; Uchechukwu Prince Okite; Sampson Ibekwe Ezeugwu
Journal:  JCO Glob Oncol       Date:  2021-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.